肺癌患者的衰弱:系统综述与荟萃分析
BACKGROUND: Previous studies regarding the prevalence of frailty in patients with lung cancer and mortality in frail patients with lung cancer are inconsistent and require clarification.…
要点
- 肺癌患者衰弱患病率高达45%,应重视衰弱评估。
- 衰弱与肺癌患者死亡风险升高显著相关(HR 3.01)。
- 衰弱评估可提供重要预后信息,或为干预改善结局提供机会。
核心结论
- 肺癌患者衰弱患病率为45%,衰弱对肺癌患者生存有显著负面影响。
- 结果强调测量衰弱的重要性,可提供重要预后信息并为改善结局的干预提供机会。
研究设计与样本
- 共识别2571篇文章,最终纳入16项研究、涉及4183例患者。
主要发现
- 肺癌患者衰弱患病率为45%(95%CI 28-61;I2=99.5%;P<.0001)。
- 在肺癌患者中,衰弱与死亡风险升高相关(HR 3.01;95%CI 1.77-5.10;P<.001)。
临床怎么用
- 对肺癌患者应开展衰弱评估,以获取预后信息并识别可能从干预中获益的人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies regarding the prevalence of frailty in patients with lung cancer and mortality in frail patients with lung cancer are inconsistent and require clarification. RESEARCH QUESTION: What is the prevalence and impact of frailty in patients with lung cancer? STUDY DESIGN AND METHODS: This systematic review and meta-analysis used a combination of free-text terms and medical subject headings terms, according to the database requirements in MEDLINE/PubMed, Scopus, and Cochrane Library from inception until November 15, 2020. RESULTS: A total of 2,571 articles were identified, and 16 articles involving 4,183 patients were included for study. The prevalence of frailty in lung cancer was 45% (95% CI, 28-61; I2 = 99.5%; P < .0001). In patients with lung cancer, frailty was associated with an increased hazard ratio for mortality (hazard ratio, 3.01; 95% CI, 1.77-5.10; P < .001). INTERPRETATION: The prevalence of frailty in lung cancer is 45%, which has a significant negative impact on survival of patients with lung cancer. These results highlight the importance of measuring frailty, which provides important prognostic information, and may provide opportunities for interventions to improve outcomes in patients with lung cancer.
引用
- Komici K, Bencivenga L, Navani N, et al. Frailty in Patients With Lung Cancer: A Systematic Review and Meta-Analysis. Chest. 2022. PMID: 35217002. doi:10.1016/j.chest.2022.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。